Background: Due to the clinical challenges of treatment-resistant depression (TRD), we evaluated the efficacy of mindfulness-based cognitive therapy (MBCT) relative to a structurally equivalent active comparison condition as adjuncts to treatment-as-usual (TAU) pharmacotherapy in TRD. Methods: This single-site, randomized controlled trial compared 8-week courses of MBCT and the Health Enhancement Program (HEP), comprising physical fitness, music therapy and nutritional education, as adjuncts to TAU pharmacotherapy for outpatient adults with TRD. The primary outcome was change in depression severity, measured by percent reduction in the total score on the 17-item Hamilton Depression Rating Scale (HAM-D17), with secondary depression indicators of treatment response and remission. Results: We enrolled 173 adults; mean length of a current depressive episode was 6.8 years (SD = 8.9). At the end of 8 weeks of treatment, a multivariate analysis showed that relative to the HEP condition, the MBCT condition was associated with a significantly greater mean percent reduction in the HAM-D17 (36.6 vs. 25.3%; p = 0.01) and a significantly higher rate of treatment responders (30.3 vs. 15.3%; p = 0.03). Although numerically superior for MBCT than for HEP, the rates of remission did not significantly differ between treatments (22.4 vs. 13.9%; p = 0.15). In these models, state anxiety, perceived stress and the presence of personality disorder had adverse effects on outcomes. Conclusions: MBCT significantly decreased depression severity and improved treatment response rates at 8 weeks but not remission rates. MBCT appears to be a viable adjunct in the management of TRD.

Keywords:
Cognitive therapy, Depression, Major depressive disorder, Mindfulness meditation, Mindfulness-based psychotherapy, Treatment-resistant depression
1.
Trevino K, McClintock SM, McDonald Fischer N, Vora A, Husain MM: Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry 2014;26:222-232.
2.
Berlim MT, Turecki G: Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52:46-54.
3.
Thase ME, Rush AJ: Treatment-resistant depression; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven, 1995, pp 1081-1097.
4.
Fava M, Davidson KG: Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
5.
American Psychiatric Association: DSM-5: Diagnostic and Statistical Manual of Mental Disorders, ed 5. Arlington, American Psychiatric Association, 2013.
6.
Bschor T, Bauer M, Adli M: Chronic and treatment resistant depression: diagnosis and stepwise therapy. Dtsch Arztebl Int 2014;111:766-775; quiz 775.
7.
Janicak PG, Dowd SM: Treatment-resistant depression: an update on diagnosis and management. Psychopharm Rev 2009;44:41-43.
8.
Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, Fava M, Nierenberg AA, McGrath PJ, Warden D, Niederehe G, Hollon SD, Rush AJ: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007;164:739-752.
9.
Warden D, Trivedi MH, Wisniewski SR, Davis L, Nierenberg AA, Gaynes BN, Zisook S, Hollon SD, Balasubramani GK, Howland R, Fava M, Stewart JW, Rush AJ: Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 2007;164:1189-1197.
10.
Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, Jenaway A, Cornwall PL, Hayhurst H, Abbott R, Pope M: Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999;56:829-835.
11.
Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470.
12.
Kocsis JH, Gelenberg AJ, Rothbaum BO, Klein DN, Trivedi MH, Manber R, Keller MB, Leon AC, Wisniewski SR, Arnow BA, Markowitz JC, Thase ME: Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP trial. Arch Gen Psychiatry 2009;66:1178-1188.
13.
Brakemeier EL, Radtke M, Engel V, Zimmermann J, Tuschen-Caffier B, Hautzinger M, Schramm E, Berger M, Normann C: Overcoming treatment resistance in chronic depression: a pilot study on outcome and feasibility of the cognitive behavioral analysis system of psychotherapy as an inpatient treatment program. Psychother Psychosom 2015;84:51-56.
14.
Kenny MA, Williams JM: Treatment-resistant depressed patients show a good response to Mindfulness-based Cognitive Therapy. Behav Res Ther 2007;45:617-625.
15.
Fekadu A, Wooderson SC, Markopoulo K, Donaldson C, Papadopoulos A, Cleare AJ: What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord 2009;116:4-11.
16.
Russell JM, Hawkins K, Ozminkowski RJ, Orsini L, Crown WH, Kennedy S, Finkelstein S, Berndt E, Rush AJ: The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341-347.
17.
Greden JF: The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):26-31.
18.
Eisendrath SJ, Delucchi K, Bitner R, Fenimore P, Smit M, McLane M: Mindfulness-based cognitive therapy for treatment-resistant depression: a pilot study. Psychother Psychosom 2008;77:319-320.
19.
Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA: Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000;68:615-623.
20.
Wang L, LaBar KS, Smoski M, Rosenthal MZ, Dolcos F, Lynch TR, Krishnan RR, McCarthy G: Prefrontal mechanisms for executive control over emotional distraction are altered in major depression. Psychiatry Res 2008;163:143-155.
21.
Lozano AM, Giacobbe P, Hamani C, Rizvi SJ, Kennedy SH, Kolivakis TT, Debonnel G, Sadikot AF, Lam RW, Howard AK, Ilcewicz-Klimek M, Honey CR, Mayberg HS: A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg 2012;116:315-322.
22.
Mayberg HS: Defining the neural circuitry of depression: toward a new nosology with therapeutic implications. Biol Psychiatry 2007;61:729-730.
23.
Lutz A, Slagter HA, Dunne JD, Davidson RJ: Attention regulation and monitoring in meditation. Trends Cogn Sci 2008;12:163-169.
24.
Lutz A, Slagter HA, Rawlings NB, Francis AD, Greischar LL, Davidson RJ: Mental training enhances attentional stability: neural and behavioral evidence. J Neurosci 2009;29:13418-13427.
25.
Barnhofer T, Crane C, Hargus E, Amarasinghe M, Winder R, Williams JM: Mindfulness-based cognitive therapy as a treatment for chronic depression: a preliminary study. Behav Res Ther 2009;47:366-373.
26.
Barnhofer T, Crane C, Hargus E, Amarasinghe M, Winder R, Williams JM: The effects of mindfulness meditation on cognitive processes and affect in patients with past depression. Behav Res Ther 2009;47:366-373.
27.
Segal ZV, Bieling P, Young T, MacQueen G, Cooke R, Martin L, Bloch R, Levitan RD: Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry 2010;67:1256-1264.
28.
Kuyken W, Byford S, Byng R, Dalgleish T, Lewis G, Taylor R, Watkins ER, Hayes R, Lanham P, Kessler D, Morant N, Evans A: Study protocol for a randomized controlled trial comparing mindfulness-based cognitive therapy with maintenance anti-depressant treatment in the prevention of depressive relapse/recurrence: the prevent trial. Trials 2010;11:99.
29.
Ma SH, Teasdale JD: Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol 2004;72:31-40.
30.
Eisendrath SJ, Gillung EP, Delucchi KL, Chartier M, Mathalon DH, Sullivan JC, Segal ZV, Feldman MD: Mindfulness-based cognitive therapy (MBCT) versus the health-enhancement program (HEP) for adults with treatment-resistant depression: a randomized control trial study protocol. BMC Complement Altern Med 2014;14:95.
31.
First MB, Pincus HA: The DSM-IV text revision: rationale and potential impact on clinical practice. Psychiatr Serv 2002;53:288-292.
32.
Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
33.
Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, Greenberg R, Rifas SL, Sackeim HA: Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996;153:985-992.
34.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
35.
MacCoon DG, Imel ZE, Rosenkranz MA, Sheftel JG, Weng HY, Sullivan JC, Bonus KA, Stoney CM, Salomons TV, Davidson RJ, Lutz A: The validation of an active control intervention for mindfulness based stress reduction (MBSR). Behav Res Ther 2012;50:3-12.
36.
Segal Z, Teasdale JD, Williams MJ, Gemar MC: The mindfulness-based cognitive therapy adherence scale: inter-rater reliability, adherence to protocol and treatment distinctiveness. Clin Psychol Psychother 2002;9:131-138.
37.
Segal Z, Williams JM, Teasdale J: Mindfulness-Based Cognitive Therapy for Depression. New York, Guilford, 2002.
38.
Chartier M, Bitner R, Peng T, Coffelt N, McLane M, Eisendrath S: Adapting ancient wisdom for the treatment of depression: mindfulness-based cognitive therapy group training. Group 2010;34:319-327.
39.
Eisendrath S, Chartier M, McLane M: Adapting mindfulness-based cognitive therapy for treatment-resistant depression: a clinical case study. Cogn Behav Pract 2011;18:362-370.
40.
Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, DHEW, 1976, Publ No ADM 76-338.
41.
Arch JJ, Craske MG: Mechanisms of mindfulness: emotion regulation following a focused breathing induction. Behav Res Ther 2006;44:1849-1858.
42.
Batink T, Peeters F, Geschwind N, van Os J, Wichers M: How does MBCT for depression work? Studying cognitive and affective mediation pathways. PLoS One 2013;8:e72778.
43.
Gu J, Strauss C, Bond R, Cavanagh K: How do mindfulness-based cognitive therapy and mindfulness-based stress reduction improve mental health and wellbeing? A systematic review and meta-analysis of mediation studies. Clin Psychol Rev 2015;37:1-12.
44.
Zettle RD, Rains JC, Hayes SC: Processes of change in acceptance and commitment therapy and cognitive therapy for depression: a mediation reanalysis of Zettle and Rains. Behav Modif 2011;35:265-283.
45.
Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L: Using self-report assessment methods to explore facets of mindfulness. Assessment 2006;13:27-45.
46.
Neff KD: The development and validation of a scale to measure self-compassion. Self Identity 2003;2:223-250.
47.
Nolen-Hoeksema S, Parker LE, Larson J: Ruminative coping with depressed mood following loss. J Pers Soc Psychol 1994;67:92-104.
48.
Hayes AM, Beevers CG, Feldman GC, Laurenceau JP, Perlman C: Avoidance and processing as predictors of symptom change and positive growth in an integrative therapy for depression. Int J Behav Med 2005;12:111-122.
49.
Hayes SC, Strosahl K, Wilson KG, Bissett RT, Pistorello J, Toarmino D, Polusny MA, Dykstra TA, Batten SV, Bergan J, Stewart SH, Zvolensky MJ, Eifert GH, Bond FW, Forsyth JP, Karekla M, McCurry SM: Measuring experiential avoidance: a preliminary test of a working model. Psychol Rec 2004;54:553-578.
50.
Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J: Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007;68:1062-1070.
51.
Spielberger C, Gorush RR, Luchene RE: State-Trait Anxiety Inventory. Palo Alto, Consulting Psychologists, 1970.
52.
Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Soc Behav 1983;24:385-396.
53.
Bernstein DP, Fink L: Childhood Trauma Questionnaire. A Retrospective Self-Report. Manual. San Antonio, Psychological Corporation, 1998.
54.
Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP Jr, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003;100:14293-14296.
55.
First M, Spitzer R, Gibbon M, Williams J, Benjamin L: Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID II). New York, Biometric Research Department, 1994.
56.
Greenberg RP, Constantino MJ, Bruce N: Are patient expectations still relevant for psychotherapy process and outcome? Clin Psychol Rev 2006;26:657-678.
57.
Borkovec TD, Nau SD: Credibility of analogue therapy rationales. J Behav Ther Exp Psychiatry 1972;3:257-260.
58.
MacKinnon DP: Introduction to Statistical Mediation Analysis. New York, Taylor & Francis, 2008.
59.
MacCoon DG, MacLean KA, Davidson RJ, Saron CD, Lutz A: No sustained attention differences in a longitudinal randomized trial comparing mindfulness-based stress reduction versus active control. PLoS One 2014;9:e97551.
60.
Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ, Team SDS: Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252.
61.
Hans E, Hiller W: A meta-analysis of nonrandomized effectiveness studies on outpatient cognitive behavioral therapy for adult anxiety disorders. Clin Psychol Rev 2013;33:954-964.
62.
Brakemeier EL, Radtke M, Engel V, Zimmermann J, Tuschen-Caffier B, Hautzinger M, Schramm E, Berger M, Normann C: Overcoming treatment resistance in chronic depression: a pilot study on outcome and feasibility of the cognitive behavioral analysis system of psychotherapy as an inpatient treatment program. Psychother Psychosom 2015;84:51-56.
63.
Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR: The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-459.
64.
Kuyken W, Hayes R, Barrett B, Byng R, Dalgleish T, Kessler D, Lewis G, Watkins E, Brejcha C, Cardy J, Causley A, Cowderoy S, Evans A, Gradinger F, Kaur S, Lanham P, Morant N, Richards J, Shah P, Sutton H, Vicary R, Weaver A, Wilks J, Williams M, Taylor RS, Byford S: Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomised controlled trial. Lancet 2015;386:63-73.
65.
Chiesa A, Castagner V, Andrisano C, Serretti A, Mandelli L, Porcelli S, Giommi F: Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. Psychiatry Res 2015;226:474-483.
66.
Carvalho AF, Berk M, Hyphantis TN, McIntyre RS: The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 2014;83:70-88.
67.
McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, Barakat M, Miguelez M: Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014;156:1-7.
68.
Bieling PJ, Hawley LL, Bloch RT, Corcoran KM, Levitan RD, Young LT, Macqueen GM, Segal ZV: Treatment-specific changes in decentering following mindfulness-based cognitive therapy versus antidepressant medication or placebo for prevention of depressive relapse. J Consult Clin Psychol 2012;80:365-372.
69.
Mothes H, Klapersi S, Seelig H, Schmidt S, Fuchs R: Regular aerobic exercise increases dispositional mindfulness in men: a randomized controlled trial. Ment Health Phys Activ 2014;7:111-119.
70.
Brown KW, Ryan RM: The benefits of being present: mindfulness and its role in psychological well-being. J Pers Soc Psychol 2003;84:822-848.
71.
Williams MJ, Dalgleish T, Karl A, Kuyken W: Examining the factor structures of the Five Facet Mindfulness Questionnaire and the Self-Compassion Scale. Psychol Assess 2014;26:407-418.
72.
Fava GA: Rational use of antidepressant drugs. Psychother Psychosom 2014;83:197-204.
73.
Ionescu DF, Niciu MJ, Richards EM, Zarate CA Jr: Pharmacologic treatment of dimensional anxious depression: a review. Prim Care Companion CNS Disord 2014;16: PCC.13r01621.
74.
Williams JM, Crane C, Barnhofer T, Brennan K, Duggan DS, Fennell MJ, Hackmann A, Krusche A, Muse K, Von Rohr IR, Shah D, Crane RS, Eames C, Jones M, Radford S, Silverton S, Sun Y, Weatherley-Jones E, Whitaker CJ, Russell D, Russell IT: Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: a randomized dismantling trial. J Consult Clin Psychol 2014;82:275-286.
75.
Mohr DC, Hart SL, Julian L, Catledge C, Honos-Webb L, Vella L, Tasch ET: Telephone-administered psychotherapy for depression. Arch Gen Psychiatry 2005;62:1007-1014.
76.
Beutler LECJ: Systematic Treatment Selection: Toward Targeted Therapeutic Interventions. New York, Brunner/Mazel, 1990.
77.
Trivedi MH, Greer TL, Church TS, Carmody TJ, Grannemann BD, Galper DI, Dunn AL, Earnest CP, Sunderajan P, Henley SS, Blair SN: Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry 2011;72:677-684.
78.
Dunlop BW, Kelley ME, Mletzko TC, Velasquez CM, Craighead WE, Mayberg HS: Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. J Psychiatr Res 2012;46:375-381.
79.
Steidtmann D, Manber R, Arnow BA, Klein DN, Markowitz JC, Rothbaum BO, Thase ME, Kocsis JH: Patient treatment preference as a predictor of response and attrition in treatment for chronic depression. Depress Anxiety 2012;29:896-905.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.